Gensmyr-Singer H, Werner M, Karling P | Therap Adv Gastroenterol | 2024
The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study

Swaminathan A, Borichevsky GM, et al |  Inflamm Bowel Dis | 2024
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease

Constantine-Cooke N, Monterrubio-Gómez K, et al | Clin Gastroenterol Hepatol | 2023
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease

Gutiérrez-Díaz I, Sanz-Martinez M, et al | Eur J Pediatr | 2023
Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity

Hamberg V, Wallman JK, et al | Rheumatol Int | 2023
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis.

Hammer HB, Pedersen SL, et al | Scand J Clin Lab Invest | 2023
Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

Hemming-Harlo M, Merras-Salmio L, Nikkonen A, Kolho KL | Eur J Pediatr | 2023
Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting

Rojas Correa M, Estremera L, et al | Contemp Clin Trials Commun | 2023
DietaAnti-Inflamatoria or DAIN: A Crohn’s disease management strategy tailored for Puerto Ricans

Sabino J, Tarassishin L, Eisele C, et al |  J Crohns Colitis | 2023
Influence of Early Life Factors, including Breastmilk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease

Bergqvist V, Holmgren J, et al | Aliment Pharmacol Ther | 2022
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

Blad N, Palmqvist R, Karling P. | BMC Cancer. | 2022
Pre-diagnostic faecal calprotectin levels in patients with colorectal cancer: a retrospective study.

Chandrasekar N, Dehlsen K, et al | Nutrients | 2022
Blenderised Tube Feeds vs. Commercial Formula: Which Is Better for Gastrostomy-Fed Children?

Di Brizzi EV, Rocco A, et al | Biomedicines | 2022
Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs.

Kim ES, Tarassishin L, Eisele C, et al | Gastroenterology | 2021
Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies.

Kolho KL, Alfthan H. | Scand J Gastroenterol. | 2020
Concentration of fecal calprotectin in 11,255 children aged 0-18 years.

Ankersen DV, Weimers P, et al | World J Gastroenterol. | 2019
Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial

Goll R, Heitmann R, et al | PLoS One | 2019
Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.

Haisma SM, Galaurchi A, et al | PLoS One | 2019
Head-to-head comparison of three stool calprotectin tests for home use

Karling P, Lundgren D, et al |  Scand J Clin Lab Invest. | 2019
Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin.

Lundgren D, Eklöf V, et al | Scand J Gastroenterol | 2019
Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy.

Acevedo D, Salvador MP, et al |  J Clin Med Res. | 2018
Fecal Calprotectin: A Comparison of Two Commercial Enzymoimmunoassays and Study of Fecal Extract Stability at Room Temperature

Bergqvist V, Kadivar M, et al | Therap Adv Gastroenterol | 2018
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Nation ML, Dunne EM, et al |  Sci Rep. | 2017
Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic.

Kristensen V, Lauritzen T, et al | Clin Chem Lab Med | 2016
Patient-performed extraction of faecal calprotectin

Mirsepasi-Lauridsen HC, Bachmann Holmetoft U, et al | Scand J Gastroenterol | 2016
Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease

Vinding KK, Elsberg H, et al | Inflamm Bowel Dis | 2016
Fecal Calprotectin Measured By Patients at Home Using Smartphones–A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease

Kristensen V, Klepp P, et al | J Crohns Colitis. | 2015
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.

Kristensen V, Lauritzen T, et al | Scand J Clin Lab Invest | 2015
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods

Soto-Méndez MJ, Romero-Abal ME et al | PLoS One | 2015
Associations among Inflammatory Biomarkers in the Circulating, Plasmatic, Salivary and Intraluminal Anatomical Compartments in Apparently Healthy Preschool Children from the Western Highlands of Guatemala

Labaere D, Smismans A, Van Olmen A, et al | United European Gastroenterol J | 2014
Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

Prell C, Nagel D, et al |  BMJ Open. | 2014
Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study.

Walkowiak J, Cofta S, et al | Eur Rev Med Pharmacol Sci | 2013
Phenylketonuria is not a risk factor for gut mucosa inflammation: a preliminary observation.

Komraus M, Wos H, Wiecek S, et al | Mediators Inflamm | 2012
Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease.